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Abstract
Background and Aim: Alcohol-related liver disease (ALD) remains a leading cause of liver-related morbidity and
mortality. Age, fibrosis stage, MELD score and continued alcohol consumption predict outcome in everyday clinical
practice. In previous studies increased hepatocyte nuclear area and hepatocyte expression of p21, both markers of
senescence, were associated with increased fibrosis stage and a poor outcome in non-alcohol-related fatty liver
disease, while increased hepatocyte nuclear area was related to liver dysfunction in ALD cirrhosis. This study,
therefore, investigated the pattern of hepatocyte cell cycle phase distribution and hepatocyte p21 expression in
relation to outcome in ALD.
Methods: Liver sections from two cohorts were studied. The first comprised 42 patients across the full spectrum of
ALD. The second cohort comprised 77 patients with ALD cirrhosis. Immunohistochemistry assessed hepatocyte
expression of cell cycle phase markers and p21. Regenerating liver (n=12) and “normal” liver sections (n=5) served
as positive and negative controls, respectively.
Results: In the first cohort there was little cell cycle progression beyond G1/S phase and increased hepatocyte p21
expression (p<0.0001), which correlated independently with fibrosis stage (p=0.005) and an adverse liver-related
outcome (p=0.03). In the second cohort, both hepatocyte p21 expression (p<0.001) and MELD score (p=0.006) were
associated independently with an adverse liver-related outcome; this association was stronger with hepatocyte p21
expression (AUROC 0.74; p=0.0002) than with MELD score (AUROC 0.59; p=0.13). Further, hepatocyte p21
expression co-localised with increased hepatic stellate cell activation.
Conclusions: The findings are consistent with impaired cell cycle progression beyond the G1/S phase in ALD. The
striking independent associations between increased hepatocyte p21 expression and both fibrosis stage and an
adverse liver-related outcome in both cohorts suggests hepatocyte senescence plays an important role in ALD.
Measuring hepatocyte p21 expression is simple and cheap and in this series was a useful measure of long-term
prognosis in ALD.
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Introduction
Alcohol-related liver disease (ALD) encompasses a broad
spectrum of liver injury ranging from simple steatosis through
alcohol-related hepatitis to cirrhosis and hepatocellular
carcinoma [1–3]. The pathophysiology of ALD is complex, but
hepatocyte oxidative stress is considered a key player, as
alcohol consumption increases production of reactive oxygen
species and lowers cellular antioxidant levels through a number
of mechanisms [3,4]. Gender, genetics, the dose, duration and
type of alcohol consumed influence the development of ALD
[1–3,5]. Once established, age, fibrosis stage, severity scores
such as the Model for End-Stage Liver Disease (MELD) and
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continued alcohol consumption after diagnosis (exceeding 10g/
day) are useful indicators of prognosis [3,6].
The validity of clinical criteria in predicting outcome in ALD
has been established, but less is known of liver histology in
relation to prognosis. In one study increased hepatocyte
nuclear area was related to hepatic dysfunction (prolonged
prothrombin time and increased serum bilirubin) and hepatic
decompensation (jaundice, ascites and encephalopathy) [7].
Increased hepatocyte nuclear area suggests hepatocyte
senescence, since nuclear enlargement is a recognised
morphological characteristic of cellular senescence [8,9].
However, it is unlikely that measuring hepatocyte nuclear area
could be introduced readily into routine clinical practice as it is
time consuming and not easily automated.
Irreversible cell cycle arrest that limits the proliferative
potential of cells is a feature of cellular senescence and is
mediated by p21, a universal cell cycle inhibitor [10]. p21 also
contributes to the stability of cell cycle arrest long after the
induction of senescence [10]. Thus, it plays a vital role in
induction and maintenance of cellular senescence. Recent
studies have demonstrated the potential utility of p21
expression as a prognostic marker in malignant disease [11].
However, less is known of the prognostic implications of p21
expression in chronic inflammatory conditions such as ALD.
A recent study demonstrated that markers of senescence
including hepatocyte p21 expression predicted an adverse
liver-related outcome in patients with non-alcohol related fatty
liver disease [12]. This prompted the current study in which the
aims were to determine the pattern of cell cycle phase
distribution in hepatocytes in patients with ALD and to assess
the association between hepatocyte p21 expression and
clinical outcome.
Materials and Methods
Patients
Two cohorts of patients with ALD were studied. All patients
gave a history of sustained excessive alcohol consumption
(men >30g/d; women >20g/d). Other recognised causes of liver
disease including chronic viral hepatitis, autoimmune liver
disease, hereditary hemochromatosis, α1-antitrypsin deficiency
and Wilson’s disease were excluded with appropriate
investigations. All patients had routine haematology and
biochemistry blood tests performed at the time of liver biopsy
and were reviewed at least every 6 months until death, an
adverse liver-related outcome or the censor point. Only those
patients with complete follow-up data were included.
The first cohort comprised 42 patients within the full
spectrum of ALD who underwent liver biopsy and remained
under long-term follow-up at Cambridge University Hospitals. A
second cohort comprised 77 patients with biopsy confirmed
alcohol-related cirrhosis under long-term follow-up at University
Hospital, Southampton, which was studied to confirm the
findings in relation to outcome in the first cohort.
A composite primary endpoint was used for the analysis of
an adverse liver-related outcome. An adverse liver-related
outcome event was defined as liver-related death, liver
transplantation or the development of hepatocellular
carcinoma. Survival was determined as the time from liver
biopsy; survivors were censored at last clinic appointment.
Controls
Liver biopsy specimens were obtained from 12 patients
during the regenerative phase of acute ischaemic-reperfusion
injury following liver transplantation to serve as positive
controls for expression of the full range of cell cycle phase
markers. All of these patients made a rapid recovery after
transplantation with normal liver function at discharge from
hospital. All the liver biopsy specimens showed evidence of
regeneration on H&E-stained sections.
Liver biopsy specimens were also obtained from background
liver from five patients with colorectal cancer metastases,
which served as negative controls for cell cycle phase markers.
None of these patients had received chemotherapy prior to
liver biopsy. Needle biopsies were distant to metastases with
normal histology on H&E-stained sections.
Liver biopsy specimens
All liver tissues were obtained from formalin-fixed paraffin-
embedded liver needle biopsy specimens, in accordance with
Cambridge University Hospitals and University Hospital,
Southampton local research ethics committee guidelines and
approval. All participants provided informed, written consent for
the liver tissue to be used for research purposes. Patients were
only included in the study if the biopsy exceeded 1.5cm in
length.
Immunohistochemistry
A Bond™ machine (Leica Microsystems), was used to
perform automated immunohistochemistry. Unconjugated
mouse monoclonal anti-Mcm-2 served as a marker of cell cycle
entry (Novocastra; concentration 1:25). Unconjugated mouse
monoclonal anti-Cyclin A (Novocastra; concentration 1:25) and
unconjugated mouse monoclonal anti-PH3 (Upstate
Biotechnology; concentration 1:500) served as markers of S
phase and M phase respectively. Unconjugated mouse
monoclonal anti-p21 served as a marker of cell cycle arrest
(Dako; concentration 1:100).
Hepatocytes with brown-stained nuclei were considered
positive for Mcm-2, cyclin A, PH3 and p21 whereas
hepatocytes with blue-stained nuclei were considered negative;
differences in the intensity of staining were not taken into
consideration. Immunohistochemistry was assessed
quantitatively to ensure objectivity. All images obtained from
DotSlide digital microscope were analysed twice - using ScanR
analysis software and manually. Photomicrographs of at least
20 lobular fields were analysed for each section (at least 1000
hepatocyte nuclei were counted). There was close correlation
between the semi-automatic ScanR analysis and manual
counting (r2=0.93; p<0.0001). Mcm-2 and p21 positive
hepatocytes were expressed as a percentage of the total
number of hepatocytes; Cyclin A and PH3 were expressed as
percentage of the number of hepatocytes expressing Mcm-2.
Ten further sections, all from patients with ALD cirrhosis,
were stained with unconjugated mouse monoclonal anti-Actin
α-Smooth Muscle antibody (α-SMA; Sigma; concentration
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1:2000), a marker of activated hepatic stellate cells. Qualitative
assessment examined the geographic association between
hepatic stellate cell activation and hepatocyte p21 expression.
Interpretation of slides
Liver samples were assessed and scored using a modified
Kleiner scoring system by specialist liver histopathologists (SD
& AB), blinded to the immunohistochemistry results and clinical
outcome. Architectural staining was performed using Gordon &
Sweets’ reticulin and Chromotrope Aniline Blue (CAB) for
assessment of fibrosis stage. Hematoxylin and Eosin (H&E)
staining was used for quantification of steatosis grade and
inflammation. Fibrosis was scored from 0 (none) to 4 (cirrhosis)
and steatosis scored 0 (<5% parenchymal involvement under
low- to medium-power evaluation) to 3 (>60% parenchymal
involvement). The histological diagnosis of alcohol-related
steatohepatitis was based on evidence of hepatocellular injury
and inflammation.
Statistics
Data are shown as median (range) or number (percentage)
unless otherwise stated. A p-value of <0.05 was considered
significant. Non-parametric analysis (GraphPad prism 5, San
Diego, CA) utilising the Mann–Whitney U test or 1-way ANOVA
(Kruskal-Wallis test) was applied where data were not
distributed normally.
Logistic regression analysis was performed using SPSS 15.0
for Windows to study factors associated with fibrosis stage.
Input variables were age, sex, presence of alcohol-related
steatohepatitis and MELD score.
Log-rank test (Kaplan-Meier analysis) and Cox-regression
model were used to identify predictors of clinical outcome. For
the purpose of the Kaplan-Meier analysis alone the following
parameters were divided into two groups based on their cohort
medians: amount of alcohol consumed, hepatocyte p21
expression and MELD. In all other instances these parameters
were treated as continuous variables. Only variables with a p-
value of <0.10 on the univariate analysis were subjected to
analysis multivariate analysis (Cox-regression).
Results
Patients
The clinical and histological characteristics of 42 patients
within the spectrum of ALD (first cohort) are summarised in
table 1. The median age was 51 years (28-69); 30 (71%) were
men; 33 (43%) had ALD without histological evidence of active
hepatitis; 32 (76%) were consuming alcohol to excess at the
time of liver biopsy (median 86g/day (29-229)); the remainder
had consumed alcohol to excess in the preceding 6 months.
Patients were followed for a median 62 months (6-117) after
liver biopsy. During follow-up, 22 of 32 (69%) of those who
were consuming alcohol at the time of liver biopsy, continued to
consume alcohol. During follow-up one patient developed
hepatocellular carcinoma and nine died from liver-related
causes. None underwent liver transplantation, either because
of continued alcohol consumption or because of co-morbidity.
Five other patients died of causes unlikely to be related to liver
disease (trauma in 2 patients and 1 each with pneumonia,
myocardial infarction and cerebrovascular disease).
The clinical characteristics of 77 patients with histology
confirmed alcohol-related cirrhosis (second cohort) are
summarised in table 2; the median age was 50 years (26-80);
43 (56%) were men; all but one were consuming alcohol in
excess at the time of liver biopsy (median 164g/day (57-600)).
The median follow-up was 57 months (1-120) after liver biopsy.
During follow-up, 46 of 76 (61%) of those who were consuming
alcohol at the time of liver biopsy, continued to consume
alcohol. During follow-up, 36 (47%) died of liver-related causes
and two (3%) were considered for and underwent liver
transplantation. A further five patients died of causes unlikely to
be related to liver disease (1 each with pneumonia, metastatic
cancer, congestive cardiac failure/ischaemic heart disease,
chronic obstructive pulmonary disease and trauma).
Distribution of hepatocyte cell cycle phase markers in
the first cohort
Expression of hepatocyte Mcm-2, cyclin A, PH3 and p21
were negligible in normal liver tissue (<0.01% of hepatocytes in
the background liver with colorectal cancer metastasis).
Mcm-2 expression was higher in hepatocytes in ALD and
regenerative liver compared to normal liver, indicating cell cycle
entry of hepatocytes in both conditions (p=0.0003 and p=0.001
Table 1. Clinical and histological characteristics of 42
patients with ALD (first cohort).
 
Median (range) or Number
(percentage)
Histological features  
Steatosis (0, 1, 2, 3) 13 (31%), 16 (38%), 9 (21%), 4(10%)
Fibrosis (0, 1, 2, 3, 4) 1 (2%), 9 (22%), 8 (19%), 10(24%), 14 (33%)
Alcohol related steatohepatitis - present /
absent 24 (57%), 18 (43%)
Biochemical parameters (normal range)  
Albumin (30-51g/l) 35 (18-44)
Bilirubin (0-17µmol/l) 14 (3-291)
Alkaline phosphatase (30-135U/l) 150 (49-619)
Alanine transaminase (0-50U/l) 52 (27-176)
International Normalised Ratio 1.3 (0.9-1.5)
Platelets (150-400 x109/l) 189 (65-408)
Creatinine (35-125µmol/l) 79 (40--119)
Adverse liver-related outcome  
Liver-related deaths 9 (21%)
Decompensation/Liver failure (+/- MOF) 6 (14%)
Variceal bleed 1 (2%)
ALD and sepsis 2 (5%)
Liver transplantation 0 (0%)
Hepatocellular carcinoma 1 (2%)
MOF: Multiorgan failure.
doi: 10.1371/journal.pone.0072904.t001
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respectively; Figure 1). However, hepatocyte Mcm-2
expression was lower in ALD compared to regenerating liver
(7.3% vs. 22.7%; p=0.0009; Figure 1).
The proportion of hepatocytes that expressed cyclin A (S
phase) in relation to the proportion of hepatocytes that were
Mcm-2 positive was much lower in ALD compared to
regenerating liver (0.9% and 11.3%, p<0.0001; Figure 1). The
proportion of hepatocytes that expressed PH3 (M phase) in
relation to the proportion of hepatocytes that were Mcm-2
positive was also lower in ALD compared to regenerating liver
(0.5% and 2.9%, p<0.0001; Figure 1). Hepatocyte p21 (cell
cycle inhibitor) expression was considerably higher in ALD
compared to regenerating liver (35.6% vs. 5.6%, p<0.0001;
Figure 1).
Hepatocyte p21 expression and its associations - first
and second cohorts
In the first cohort, there was a positive correlation between
hepatocyte p21 expression and fibrosis stage (p=0.002; Figure
2), which remained significant (p=0.005) after multivariate
analysis when controlled for age, sex, presence of alcohol-
related steatohepatitis and MELD score. A similar analysis
could not be undertaken in the second cohort as it only
included patients with established cirrhosis (Figure 3).
Areas of liver with increased hepatic stellate cell activation
were associated with higher hepatocyte p21 expression; in
contrast, areas of liver with fewer activated hepatic stellate
cells were associated with lower hepatocyte p21 expression,
even within the same tissue (Figure 2).
Expression of p21 was diffuse and not restricted to periportal
or perivenular zones. Hepatocyte p21 expression was not
associated in either cohort with the steatosis grade (p=0.14 and
p=0.36, respectively) or with the presence of alcohol-related
steatohepatitis (p=0.07 and p=0.20, respectively).
Table 2. Clinical characteristics in 77 patients with ALD &
cirrhosis (second cohort).
 
Median (range) or Number
(percentage)
Biochemical parameters (normal range)  
Albumin (30-51g/l) 26 (11-42)
Bilirubin (0-17µmol/l) 44 (7-627)
Alkaline phosphatase (30-135U/l) 307 (30-1760)
Alanine transaminase (0-50U/l) 34 (11-393)
International Normalised Ratio 1.4 (1.0-4.5)
Creatinine (35-125µmol/l) 73 (21-314)
Adverse liver-related outcome  
Liver-related deaths 36 (47%)
Decompensation (+/- MOF) 20 (26%)
Variceal bleed 13 (17%)
ALD and sepsis 3 (4%)
Liver transplantation 2 (3%)
Hepatocellular carcinoma 0 (0%)
MOF: Multiorgan failure.
doi: 10.1371/journal.pone.0072904.t002
Hepatocyte p21 expression demonstrated no correlation with
either MELD score (p=0.11 and p=0.36) or the amount of
alcohol consumed at the time of liver biopsy (p=0.20 and
p=0.94) in the first and second cohorts, respectively. In
addition, in the first cohort, there was no difference in
hepatocyte p21 expression between those who were
consuming and those not consuming alcohol at the time of liver
biopsy (p=0.07). A similar analysis was not carried out in the
second cohort, as only one patient was not consuming alcohol
at the time of liver biopsy.
In the first cohort, hepatocyte p21 expression correlated
positively with prothrombin time (p=0.0003; Figure 2) but
showed no association with serum albumin level (p=0.13). In
the second cohort, however, hepatocyte p21 expression
demonstrated a positive correlation with prothrombin time
(p=0.04; Figure 2) and an inverse correlation with serum
albumin (p=0.03; Figure 2). Hepatocyte p21 expression was
not associated with serum total bilirubin in either cohort (p=0.46
and p=0.62, respectively).
Hepatocyte p21 expression and outcome - first and
second cohorts
Analysis with the Log-rank test (univariate analysis) in the
first cohort revealed that patients with higher hepatocyte p21
expression (above the median) were more likely to develop an
adverse liver-related outcome than those with lower p21
expression (p=0.03; Figure 4a). Age (p=0.91), sex (p=0.65),
fibrosis stage (p=0.83), alcohol-related steatohepatitis (p=0.82),
MELD score (p=0.52), the quantity of alcohol consumed at the
time of liver biopsy (p=0.22) and continued alcohol
consumption during follow-up (p=0.11) were not related to an
adverse liver-related outcome. Multivariate analysis was not
performed in the first cohort as only p21 expression
demonstrated an association with liver-related outcome (with p-
value <0.10) on univariate analysis.
Analysis with the Log-rank test (univariate analysis) in the
second cohort revealed that patients with higher hepatocyte
p21 expression (p < 0.0001; Figure 4b), higher MELD score
(p=0.03; Figure 4c) and excess alcohol consumption at the
time of biopsy (p=0.03; Figure 4d) were each associated with
an adverse liver-related outcome (table 3). As with the first
cohort, age (p=0.43), sex (p=0.27), alcohol-related
steatohepatitis (p=0.51) and alcohol consumption during follow-
up (p=0.55) were not related to outcome. On Cox regression
analysis (multivariate analysis) both MELD score (HR=1.05;
95% CIHR 1.01-1.10; p=0.008) and hepatocyte p21 expression
(HR=24.56; 95% CIHR 5.10-118.35; p<0.001) but not the
quantity of alcohol consumed at the time of biopsy (HR=0.99;
95% CIHR 0.99-1.00; p=0.07), were associated independently
with an adverse liver-related outcome (table 3). However,
hepatocyte p21 expression was associated more closely with
an adverse liver-related outcome (AUROC 0.74; 95% CI
0.63-0.85; p=0.0002; Figure 5) than MELD score (AUROC
0.59; 95% CI 0.47-0.72; p=0.13; Figure 5). Combining MELD
score with hepatocyte p21 expression made no improvement to
the predictive value of hepatocyte p21 expression alone
(AUROC of MELD score plus p21 0.76 versus AUROC of
hepatocyte p21 alone 0.74; p=0.70). With a cut-off at 25%,
Hepatocyte Senescence in ALD
PLOS ONE | www.plosone.org 4 September 2013 | Volume 8 | Issue 9 | e72904
33% and 50%, hepatocyte p21 expression had 95%, 84% and
66% sensitivity and 33%, 49% and 77% specificity,
respectively, in predicting an adverse liver-related outcome.
In the second cohort, the time to an adverse liver-related
outcome was much shorter in patients with hepatocyte p21
expression above the median compared to patients with lower
hepatocyte p21 expression (12 months (1-82) versus 40
months (1-90); p=0.04).
Discussion
In this study, the distribution of hepatocyte cell cycle phase
markers and hepatocyte p21 expression were examined in the
first cohort, which was selected carefully from a larger series
such that alcohol was the only known risk factor for liver
disease, long-term follow-up was assured, liver sections were
of adequate size and the patients covered a broad spectrum of
liver histology. This revealed impaired hepatocyte cell cycle
progression beyond G1/S phase and increased hepatocyte p21
expression. The association between hepatocyte p21
expression and a subsequent adverse liver-related outcome
prompted further investigation. Thus, a further well-defined
group of patients that had undergone liver biopsy and long term
follow-up were recruited to study the association between
hepatocyte p21 expression and clinical outcome. Since
hepatocyte p21 expression was higher in advanced fibrosis
and an adverse liver-related outcome is more common in
patients with advanced fibrosis, the second cohort was
selected such that all patients had ALD cirrhosis. The strong
relation between increased hepatocyte p21 expression and an
adverse liver-related outcome was confirmed in this second
cohort. These data are consistent with previous data in patients
Figure 1.  The distribution of cell cycle phase markers in the first cohort and controls.  Examples of the immunohistochemical
staining of Mcm-2, cyclin A, PH3 and p21 in regenerating liver (positive control tissue), liver from a representative patient with ALD
and normal liver (negative control tissue). Hepatocyte Mcm-2 expression was higher in ALD and regenerating liver (positive control)
compared to normal liver (negative control). Cyclin A and PH3 expression were lower in ALD compared to regenerating liver. In
contrast hepatocyte p21 expression was higher in ALD compared to regenerating liver.
doi: 10.1371/journal.pone.0072904.g001
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with non-alcohol-related fatty liver disease which revealed a
close link between hepatocyte p21 expression, fibrosis stage
and increased liver related morbidity and mortality [12].
Figure 3.  Differential hepatocyte p21 expression in the
second cohort.  Figure 3 shows fibrosis using reticulin staining
(above) and hepatocyte p21 expression (below) in a patient
with ALD cirrhosis in second cohort.
doi: 10.1371/journal.pone.0072904.g003
Oxidative stress, such as ethanol-induced oxidative stress,
causes double-strand DNA breaks [13], which in turn leads to
cellular senescence and permanent cell cycle arrest [8]. Such
senescent cells display DNA content typical of the G1 phase of
cell cycle [9]. The presence of Mcm-2, which is present
throughout the cell cycle, in both regenerating liver and ALD
shows the replicative response of hepatocyte to acute
ischaemia and alcohol-related insult, respectively. However,
the relative reduction in Cyclin A expression (marker of S
phase) and PH3 expression (marker of M phase) in ALD
compared to regenerating liver indicates impaired cell cycle
progression beyond the G1/S phase in ALD. This is
corroborated by a marked increase in hepatocyte p21
expression in ALD compared to regenerating liver, since p21 is
a universal cell cycle inhibitor which exerts its effect at the G1/S
phase transition [14]. It was notable that hepatocyte p21
expression in ALD exceeded Mcm-2 expression substantially;
this disparity is not explained readily. This may be due to
depletion of Mcm proteins in hepatocytes in permanent cell
cycle arrest as described previously [15] to prevent completion
of mitosis or direct induction of p21, perhaps due to cellular
stress, in hepatocytes that have not entered the cell cycle.
There was progressive increase in hepatocyte p21
expression with increasing fibrosis stage in ALD. This
observation, together with the increase in hepatocyte nuclear
area in ALD cirrhosis described previously [7] and previous
Figure 2.  Hepatocyte p21 expression in relation to fibrosis stage and laboratory indices.  Hepatocyte p21 expression
demonstrated an association with fibrosis stage [2a] in the first cohort; the proportion of hepatocytes that expressed p21 increased
with increasing fibrosis stage.
Areas of increased α-SMA expression (a marker of activated hepatic stellate cells) were associated with higher hepatocyte p21
expression (2b) than those areas with less α-SMA expression, which were associated with lower hepatocyte p21 expression (2c)
even within the same tissue.
Expression of hepatocyte p21 correlated positively with prothrombin time in both cohorts (Figure 2d & 2e, respectively) and
correlated negatively with serum albumin in the second cohort (Figure 2f).
doi: 10.1371/journal.pone.0072904.g002
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data linking both increased hepatocyte p21 expression and
increased hepatocyte nuclear area with fibrosis stage in non-
alcohol-related fatty liver disease [12], strengthens the notion
Figure 4.  Hepatocyte p21 expression, MELD score and
alcohol consumption at the time of liver biopsy in relation
to an adverse liver-related outcome.  Kaplan-Meier analysis
in 42 patients in the first cohort, divided according to
hepatocyte p21 expression above the median [red line] or
below the median [black line]) from the time of liver biopsy to
outcome or censor point by log-rank test (p=0.03) [4a].
Kaplan-Meier analysis of 77 patients in the second cohort from
the time of liver biopsy to outcome or censor point by log-rank
test - divided according to p21 expression above the median
[red line] or below the median [black line] (p<0.0001) [4b];
MELD score above the median [red line] or MELD score below
the median [black line] (p=0.03) [4c]; alcohol consumption
above the median [red line] or alcohol consumption below the
median [black line] (p=0.03) [4d].
doi: 10.1371/journal.pone.0072904.g004
Table 3. Univariate and multivariate analysis of factors that
influence an adverse liver-related outcome in the second
cohort.
 Univariate analysis Multivariate analysis
 HR (95% CIHR) p-value HR (95% CIHR) p-value
Age 0.77 (0.40-1.48) 0.43   
Sex 0.69 (0.36-1.33) 0.27   
Alcohol consumption
at biopsy 2.02 (1.05-3.92) 0.03 0.99 (0.99-1.00) 0.076
Alcoholic
steatohepatitis 1.36 (0.47-3.97) 0.51   
MELD score 2.03 (1.05-3.93) 0.03 1.05 (1.01-1.10) 0.006
p21 3.97 (2.03-7.77) < 0.0001 24.56(5.10-118.35) < 0.001
Alcohol consumption
during follow-up 1.21 (0.62-2.36) 0.55   
doi: 10.1371/journal.pone.0072904.t003
that senescent hepatocytes accumulate with progressive
fibrosis. It is unclear whether senescent hepatocytes drive
fibrosis, perhaps by activating hepatic stellate cells, or if
hepatocyte senescence and fibrosis are both consequences of
the same alcohol-related insult. The geographic association
between hepatocyte p21 expression and hepatic stellate cell
activation (shown by α-SMA expression) demonstrated in this
study supports the notion that hepatocyte senescence,
activation of hepatic stellate cells and fibrosis are linked. A
recent study shone light on the causal relation between
hepatocyte senescence and hepatic stellate cell activation by
demonstrating reduced collagen deposition, reduced α-SMA, a
marker of hepatic stellate cell activation, and reduced hepatic
p21 expression, the downstream target of p53, in p53-deficient
mice after 8 weeks of MCD diet [16].
Hepatocyte proliferation is critical for liver regeneration [17].
Accumulation of senescent hepatocytes, which are insensitive
to mitotic stimuli, may impair the reserve for liver regeneration.
In addition, the association between increased hepatic nuclear
area and hepatic dysfunction [7,12] suggests that senescent
hepatocytes may not function as normal mature hepatocytes.
In the present study, there was also an association between
senescence, measured as increased hepatocyte p21
expression and impaired liver synthetic function (increasing
prothrombin time and decreasing serum albumin level). Thus,
accumulation of senescent hepatocytes may contribute to loss
of functional hepatic mass and with sufficient accumulation of
such cells leading eventually to liver decompensation and liver
related death, accounting for the strong link between
hepatocyte p21 expression and an adverse liver-related
outcome. Previous studies in cells other than hepatocytes have
shown loss of function specific to that cell type during
senescence [18]. If this proves true for hepatocytes in ALD,
then that might explain, at least in part, the clinical and
biochemical dysfunction with progressive liver disease - since
up to 87% of hepatocytes in ALD in this series expressed p21
Figure 5.  ROC curves comparing hepatocyte p21
expression alone, MELD score alone and hepatocyte p21
expression plus MELD score in predicting an adverse liver
related outcome in patients with alcohol-related
cirrhosis.  The area under the receiver operating characteristic
(ROC) curves for hepatocyte p21 expression alone (0.74),
MELD score alone (0.59) and hepatocyte p21 plus MELD score
(0.76) are shown
doi: 10.1371/journal.pone.0072904.g005
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and may have impaired function. The absence of an
association between hepatocyte p21 expression and serum
bilirubin, an important maker of liver dysfunction in general and
in ALD in particular, suggests that an elevated bilirubin is not a
surrogate marker of senescence and may perhaps reflect
superimposed bacterial sepsis, which is common in ALD.
The relation between hepatocyte p21 expression and
outcome is noteworthy. Indeed in this series with ALD, the
relation between hepatocyte p21 expression and outcome was
stronger than that for MELD score, fibrosis stage, alcohol-
related steatohepatitis or continued alcohol consumption.
Hepatocyte p21 expression can be assessed readily by
immunohistochemistry (much more readily than nuclear area)
and has the potential to be useful for assessing prognosis in
day-to-day clinical practice, stratification in future clinical trials
in ALD and even when liver transplantation is being considered
and the prognosis remains uncertain.
The first cohort comprised a consecutive series of patients
with all stages of fibrosis and all manifestations of alcohol-
related steatohepatitis. Although patients were selected for
single aetiology, tissue quality and extended follow-up, in every
other respect, this cohort reflects ‘real world everyday practice’.
The second cohort included only patients with cirrhosis but with
all grades of alcohol-related steatohepatitis. Both cohorts were
selected carefully only to include those with biopsy-proven
ALD, those with adequate tissue for meaningful analysis, with
adequate long-term follow-up and all necessary data available
including information on alcohol consumption during follow-up.
Information on the quantity of alcohol consumed during
follow-up was self-reported and may be less accurate and this
remains a limitation of the study. A further limitation was that
information regarding nutritional status, which may have
influenced the clinical outcome, was not available in a sufficient
number of patients for analysis.
In conclusion, this study demonstrated that impaired cell
cycle progression in hepatocytes, hepatocyte senescence and
progressive fibrosis in ALD were inter-related. Further, there
was a strong relation between the proportion of senescent
hepatocytes and an adverse liver-related outcome. Similar
findings were demonstrated in non-alcohol-related fatty liver
disease [12]. It is plausible that cellular senescence is a
common response of the hepatocyte to cellular stress and
injury and not limited to a particular aetiology.
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